Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

139.03 +1.56 (+1.13%)
Streaming Delayed Price Updated: 12:20 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,025
Open 136.54
Bid (Size) 138.59 (2)
Ask (Size) 139.28 (1)
Prev. Close 137.47
Today's Range 132.50 - 144.79
52wk Range 55.17 - 146.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GeneDx (WGS) Q3 2025 Earnings Call Transcript
GeneDx (WGS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
GeneDx Holdings Corp (NASDAQ:WGS) Q3 2025 Earnings Beat Estimates and Drive Stock Higher
GeneDx Q3 2025 earnings crush estimates with 52% revenue growth. Strong exome/genome test demand and raised 2025 guidance fuel investor optimism. 
Via Chartmill
Topics Earnings

Performance

YTD
+74.6%
+74.6%
1 Month
+22.0%
+22.0%
3 Month
+51.5%
+51.5%
6 Month
+18.9%
+18.9%
1 Year
+148.0%
+148.0%

More News

Read More
Earnings Scheduled For October 28, 2025
Via Benzinga
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
From GeneDx
Via Business Wire
GeneDx Hldgs's Earnings: A Preview
Via Benzinga
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
From GeneDx
Via Business Wire
4 Analysts Assess GeneDx Holdings: What You Need To Know
Via Benzinga
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
From GeneDx
Via Business Wire
This WillScot Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
From GeneDx
Via Business Wire
GeneDx Holdings Corp (NASDAQ:WGS) Presents a High-Growth Momentum and Technical Breakout Case
Via Chartmill
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
From GeneDx
Via Business Wire
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
From GeneDx
Via Business Wire
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
From GeneDx
Via Business Wire
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
From GeneDx
Via Business Wire
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
From GeneDx
Via Business Wire
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
From GeneDx
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
From GeneDx
Via Business Wire
GeneDx Holdings Corp (NASDAQ:WGS) Exhibits Strong Growth Momentum and Positive Technical Setup
Via Chartmill
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
From GeneDx
Via Business Wire
Assessing GeneDx Holdings: Insights From 5 Financial Analysts
Via Benzinga
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is GeneDx Holdings Corp. - Class A Common Stock publicly traded?
Yes, GeneDx Holdings Corp. - Class A Common Stock is publicly traded.
What exchange does GeneDx Holdings Corp. - Class A Common Stock trade on?
GeneDx Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeneDx Holdings Corp. - Class A Common Stock?
The ticker symbol for GeneDx Holdings Corp. - Class A Common Stock is WGS on the Nasdaq Stock Market
What is the current price of GeneDx Holdings Corp. - Class A Common Stock?
The current price of GeneDx Holdings Corp. - Class A Common Stock is 139.03
When was GeneDx Holdings Corp. - Class A Common Stock last traded?
The last trade of GeneDx Holdings Corp. - Class A Common Stock was at 10/29/25 12:20 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.